Covid-19 Treatment: Russia sees promising results in early trials of Favipiravir
Moscow: A candidate drug for treating the new coronavirus, Favipiravir, has produced promising results in early clinical trials in Russia, according to the Russian Direct Investment Fund, which provided 150 million roubles ($2 million) in funding for the project.
RDIF head Kirill Dmitriev said 60% of the 40 patients taking tablets of Favipiravir, which was first developed in Japan under the name Avigan, tested negative for the virus within five days and said the treatment could cut coronavirus recovery times in half.
Avigan, known generically as Favipiravir, was developed in the late 1990s by a company later bought by Fujifilm. The drug works by short-circuiting the reproduction mechanism of certain RNA viruses such as influenza. Favipiravir is also undergoing trials in India by Glenmark Pharmaceuticals Ltd.
The clinical trial of 330 patients will be finished by May.
Experts say early tests showed minimal side effects, although more tests were needed before pregnant women can use it. Avigan in Japan was found to cause birth defects.
Read also: Glenmark begins Phase 3 Clinical Trials on Antiviral Favipiravir for coronavirus in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.